Systemic immune reactivity in patients with ocular demodicosis

Authors

  • Л. М. Velychko SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»
  • O. V. Bogdanova SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»
  • N. I. Khramenko SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»
  • M. B. Makarova SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»
  • O. G. Linchevska SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»
  • S. I. Poliakova SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»
  • I. V. Tsukanova SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

DOI:

https://doi.org/10.31288/Ukr.j.ophthalmol.202617176

Keywords:

Demodex, blepharitis, inflammation, immunology, CD3, CD16, eyelids

Abstract

Purpose: To assess the status of the immune system in patients with ocular demodicosis.
Methods: This study was conducted at the Immunology Laboratory and Clinical Diagnostics Laboratory of SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”. We examined 47 patients with chronic ocular demodicosis (mean age, 29.7 ± 17.4 years) who were treated at the Consultative Polyclinic of SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine”. The control group included 20 healthy donors (mean age, 32.8 ± 15.2 years). Monoclonal antibodies (McABs) and fluorescence microscopy were used in immunohistochemistry studies. Spreadsheets and IBM SPSS Statistics (Demo) software were employed for statistical analysis.
Results: Patients with ocular demodicosis exhibited changes in immune system function, reductions in neutrophil phagocytic activity and the absolute count and percentage of CD3 and increases in the neutrophil-to-lymphocyte ratio and percentage of CD16. Treatment for ocular demodicosis should include not only anti-parasitic therapy, but also anti-inflammatory therapy and immune correction.

Author Biographies

Л. М. Velychko , SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Velychko L.M., Dr Sc (Med) and Head, Immunology Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

O. V. Bogdanova, SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Bogdanova O. V., Cand Sc (Biol) and Researcher, Immunology Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

N. I. Khramenko, SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Khramenko N. V., Cand Sc (Med) and Head, Functional Diagnostics Department, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

M. B. Makarova, SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Makarova M. B., Cand Sc (Med) and   Head, Clinical Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

O. G. Linchevska , SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Linchevska O. G., Head, Clinical Diagnostics Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

S. I. Poliakova, SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Poliakova S. I., Dr Sc (Med) and Senior Researcher, Ocular Oncology Department, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

I. V. Tsukanova , SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine»

Tsukanova I. V., Junior Researcher, Cand Sc (Med), Ocular Oncology Department, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

References

1. Rhee MK, Yeu E, Barnett M, Rapuano CJ, Dhaliwal D, Nichols K K, et al. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Eye Contact Lens. 2023 Aug 1;49(8):311-318. https://doi.org/10.1097/ICL.0000000000001003

2. Cheng AMS, Sheha H, Tseng SCG. Recent advances on ocular Demodex infestation. Curr Opin Ophthalmol. 2015;26:295-300 https://doi.org/10.1097/ICU.0000000000000168

3. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):505-10. https://doi.org/10.1097/ACI.0b013e32833df9f4

4. Zhang AC, Muntz A, Wang M, Craig JP, Downie LE. Ocular demodex: A systematic review of the clinical literature. Ophthalmic Physiol Opt. 2020;40:389-432.https://doi.org/10.1111/opo.12691

5. Biernat MM, Rusiecka-Ziółkowska J, Piątkowska E, Helemejko I, Biernat P, Gościniak G. Occurrence of demodex species in patients with blepharitis and in healthy individuals: A 10-year observational study. Jpn J Ophthalmol. 2018;62:628-633 https://doi.org/10.1007/s10384-018-0624-3

6. Kim JH, Chun YS, Kim JC. Clinical and immunological responses in ocular demodecosis. J Korean Med Sci. 2011 Sep; 26(9):1231-7.https://doi.org/10.3346/jkms.2011.26.9.1231

7. Kim JT, Lee SH, Chun YS, Kim JC. Tear cytokines and chemokines in patients with Demodex blepharitis. Cytokine. 2011 Jan;53(1):94-9. https://doi.org/10.1016/j.cyto.2010.08.009

8. Pyzia J, Mankowska K, Czepita M, Kot K, Lanocha-Arendarczyk N, Czepita D. Demodex Species and Culturable Microorganism Co-Infestations in Patients with Blepharitis. Life (Basel). 2023 Aug 29;13(9):1827. https://doi.org/10.3390/life13091827

9. Zou D, Lu X, Song F, Zhong X, Chen H, Zhang J et al. Characteristics of bacterial community in eyelashes of patients with Demodex blepharitis. Parasit Vectors. 2024 Feb 14;17(1):64. https://doi.org/10.1186/s13071-024-06122-x

10. Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Immunocytochemistry in tumor diagnosis]. Kyiv: Morion; 2003. Russian.

11. Forget P, Khalifa C, Defour J, Latinne D, Van Pel M, De Kock M What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017 Jan 3;10(1):12. https://doi.org/10.1186/s13104-016-2335-5

12. Zahorec R Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474-488. https://doi.org/10.4149/BLL_2021_078

13. Altunisik N, Turkmen D, Sener S. Investigation of the relationship between inflammatory blood parameters and rosacea and demodex infestation. J Cosmet Dermatol. 2020 Aug;19(8):2105-2108. https://doi.org/10.1111/jocd.13254

14. Certificate of copyright registration for work № 119857 dated 19.06.2023. Аuthors: Khramenko NI, Drozhzhyna GI, Velychko LM, Bogdanova OV. [Method for diagnosing recurrence in patients with recurrent stromal herpetic keratitis based on the ratio of neutrophils to lymphocytes in peripheral blood].

15. Friedman MG. Antibodies in human tears during and after infection. Surv Ophthalmol. 1990 Sep-Oct;35(2):151-7. doi: 10.1016/0039-6257(90)90070-c. https://doi.org/10.1016/0039-6257(90)90070-C

16. Puchkovskaya NA, Shulgina KS, Minev MG, Ignatov RK. [Immunology of Eye Pathology]. Moscow: Meditsina; 1983. Russian.

17. Artemov О, Lytvynenko М, Neskoromna N, Chebotarova S, Prus R, Oluwafemi A, et al. Pathomorphosis of eyelid tumor pathology in demodectic infection. Inter Collegas. 2024;11(1): 5-10. https://doi.org/10.35339/ic.11.1.aln

18. Artemov ОV, Lytvynenko МV, Chumachenko IV, Bondarenko AV, Dotsenko NV Ostapchuk KV, et al. The influence of the demodex mite on the morphological picture of eyelid papilloma. Georgian Med News. 2024 Jul-Aug:(352-353):50-54.

19. Chatterjee S, Gupta J, Srinivas SP, Rao SK. Demodex and the eye - A review. Indian J Ophthalmol. 2024 Dec 23;73(1):10-18. https://doi.org/10.4103/IJO.IJO_1591_24

20. Martínez-Pulgarín DF, Ávila MY, Rodríguez-Morales AJ. Interventions for Demodex blepharitis and their effectiveness: A systematic review and meta-analysis. Cont Lens Anterior Eye. 2021 Dec;44(6):101453. https://doi.org/10.1016/j.clae.2021.101453

21. Navel V, Mulliez A, Benoist d'Azy C, Baker JS, Malecaze J, Chiambaretta Fet al. Efficacy of treatments for Demodex blepharitis: A systematic review and meta-analysis.. Ocul Surf. 2019 Oct;17(4):655-669. https://doi.org/10.1016/j.jtos.2019.06.004

Downloads

Published

2026-02-26

How to Cite

[1]
Velychko Л.М. et al. 2026. Systemic immune reactivity in patients with ocular demodicosis. Ukrainian Journal of Ophthalmology . 1 (Feb. 2026), 71–76. DOI:https://doi.org/10.31288/Ukr.j.ophthalmol.202617176.

Issue

No. 1 (2026): Ukrainian Journal of Ophthalmology

Section

Clinical Ophthalmology

License

Copyright (c) 2026 Velychko L. M., Bogdanova O. V., Khramenko N. I., Makarova M. B., Linchevska O. G.; Poliakova S. I., Tsukanova I. V.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

  1. Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
  2. The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
  3. Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
  4. Archiving the pre-print (pre-refereeing manuscript version) not allowed.

Most read articles by the same author(s)

1 2 3 > >> 

Similar Articles

1 2 3 4 5 6 7 > >> 

You may also start an advanced similarity search for this article.